A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder

Neoadjuvant cisplatin‐based chemotherapy improves survival in muscle‐invasive urothelial cancer, with MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) considered the standard regimen. Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment.

[1]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[2]  D. Amadori,et al.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.

[3]  R. Dienstmann,et al.  Phase II trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive bladder cancer: Preliminary results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Aprikian,et al.  Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. , 2006, The Journal of urology.

[5]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[7]  D. Jonker,et al.  A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer. , 2004, The Canadian journal of urology.

[8]  N. James,et al.  A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer , 2004, British Journal of Cancer.

[9]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[10]  M. Alloisio,et al.  Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Scagliotti,et al.  A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Mazumdar,et al.  Evaluation of Drug Delivery and Survival Impact of Dose-Intense Relative to Conventional-Dose Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy in Urothelial Cancer , 2000, Cancer investigation.

[15]  G. Griffiths.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists , 1999 .

[16]  M. Droller.  Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial , 1999, The Lancet.

[17]  S. Lerner.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. , 1999, Lancet.

[18]  I. Tannock,et al.  High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. , 1998, The Journal of urology.

[19]  H. Scher,et al.  Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Vogelzang,et al.  The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. , 1992, The Journal of urology.

[21]  H. Scher.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, The Journal of urology.